CSIMarket
 
Enzon Pharmaceuticals inc   (ENZN)
Other Ticker:  
 
 
Price: $0.0828 $0.00 -0.957%
Day's High: $0.0828 Week Perf: 3.11 %
Day's Low: $ 0.07 30 Day Perf: -6.02 %
Volume (M): 3 52 Wk High: $ 0.27
Volume (M$): $ 0 52 Wk Avg: $0.15
Open: $0.08 52 Wk Low: $0.06



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 74
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) 1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Enzon Pharmaceuticals Inc
Enzon Pharmaceuticals Inc is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapies for the treatment of cancer and other serious diseases. The company was founded in 1981 and is headquartered in Piscataway, New Jersey.

Enzon Pharmaceuticals has a unique approach to drug development, using a proprietary technology platform called PEGylation. PEGylation involves attaching polyethylene glycol (PEG) chains to therapeutic proteins or drug molecules, which can enhance their efficacy and prolong their circulation time in the body.

The company's product portfolio includes several PEGylated drugs that have been approved by regulatory authorities and are marketed in the United States and other countries. These drugs target a range of diseases, including breast cancer, lung cancer, and multiple myeloma.

In addition to its commercial products, Enzon Pharmaceuticals also has a robust pipeline of drug candidates in various stages of development. The company actively engages in strategic collaborations and partnerships to leverage its technology platform and expand its product portfolio.

Enzon Pharmaceuticals is committed to advancing patient care and improving outcomes. Through its innovative therapies and ongoing research efforts, the company strives to make a meaningful impact in the field of biopharmaceuticals.


   Company Address: 20 Commerce Drive (Suite 135) Cranford 7016 NJ
   Company Phone Number: 980-4500   Stock Exchange / Ticker: ENZN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Enzon Pharmaceuticals Inc

Enzon Pharmaceuticals Inc Generates Impressive Revenue of $0.622 Million in Q3 2023

Enzon Pharmaceuticals Inc is a pharmaceutical company that recently reported its financial results for the period ending September 30, 2023. The company announced a revenue of $0.622 million, which represents an improvement compared to the previous year's reporting period. Additionally, Enzon Pharmaceuticals Inc achieved a net earnings of $0.321 million, indicating a significant improvement from a net deficit of $-0.015 million in the same period last year.
These positive financial results reflect the company's ability to generate revenue and increase profitability. Enzon Pharmaceuticals Inc's management should be commended for their efforts in turning around the financial performance of the company.

Enzon Pharmaceuticals Inc

Enzon Pharmaceuticals Faces Uncertain Future with Alarming Plunge to Just $0.553 Million Revenue in Recent Fiscal Period

Enzon Pharmaceuticals Inc. (ENZN) is facing a challenging future as the company reported lower revenue and net earnings in the April to June 2023 fiscal period. The company posted only $0.553 million in revenue, a disappointing figure that indicates a lack of growth and potential for profitability.
In the same reporting period a year ago, Enzon Pharmaceuticals Inc. suffered a net deficit of $-0.213 million, highlighting the company's struggle to generate positive earnings. Although there was an improvement to a net earnings of $0.183 million in the current fiscal span, this figure remains significantly lower, indicating that the company has a long way to go before achieving consistent profitability.

Enzon Pharmaceuticals Inc

Enzon Pharmaceuticals Inc Skyrockets Revenue to $0.447 Million, Surpassing Last Year's Performance

Enzon Pharmaceuticals Inc, a biotechnology and pharmaceuticals company, has just released its financial report for the first quarter of 2023. The report shows that the company generated revenue of $0.447 million during the quarter, which represents a significant increase in revenue compared to the same reporting period a year ago.
Furthermore, the report also shows that Enzon Pharmaceuticals Inc achieved earnings of $0.197 million in the financial first quarter of 2023, a significant improvement from the net loss of $-0.291 million in the comparable financial reporting period from a year ago. This improvement in the company's performance is a result of their efforts to improve operational efficiency and optimize their product offerings.






 

Enzon Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com